External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme

Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality assessment (EQA) scheme fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito Abate, Riziero, Cheetham, Melanie H., Fairley, Jennifer A., Pasquale, Raffaella, Sacco, Alessandra, Nicola, Wolstenholme, Deans, Zandra C., Patton, Simon J., Normanno, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931778/
https://www.ncbi.nlm.nih.gov/pubmed/36355212
http://dx.doi.org/10.1007/s00428-022-03444-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931778/
https://www.ncbi.nlm.nih.gov/pubmed/36355212
http://dx.doi.org/10.1007/s00428-022-03444-y

Ejemplares similares